4 completed, 3 recruiting. 5 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Immatics US, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTengine® IMA203 Combined With mRNA-4203 IMA203, mRNA-4203 - Cutaneous Melanoma, Synovial Sarcoma | Phase 1 | Recruiting | Immatics US, Inc. | 15 | 2025-07-25 | 2026-01-08 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics US, Inc. | 375 | 2019-05-14 | 2026-05-13 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 IMA202 Product, IMADetect® - Solid Tumor, Adult, Refractory Cancer | Phase 1 | Completed | Immatics US, Inc. | 16 | 2019-05-02 | 2025-02-04 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling Refractory Cancer, Recurrent Cancer | Completed | Immatics US, Inc. | 242 | 2019-02-26 | 2025-02-04 | |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) IMA201 Product, IMADetect® - Solid Tumor, Cancer | Phase 1 | Completed | Immatics US, Inc. | 7 | 2018-12-19 | 2025-02-04 |
| ACTolog in Patients With Solid Cancers Fludarabine, Cyclophosphamide, IMA101 product - Cancer, Solid Tumor | Phase 1 | Completed | Immatics US, Inc. | 38 | 2017-06-30 | 2025-02-04 |
Neoplasms (5) · Recurrence (3) · Melanoma (2) · Ovarian Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Melanoma, Cutaneous Malignant (1) · Neoplasm Metastasis (1) · Sarcoma, Synovial (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Uveal Melanoma (1)
Nivolumab (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cyclophosphamide (1) · Dacarbazine (1) · Ipilimumab (1) · Opdualag (1) · Paclitaxel (1) · Temozolomide (1) · aldesleukin (1) · atezolizumab (1) · fludarabine (1) · fludarabine phosphate (1) · lifileucel (1) · pembrolizumab (1)
United States (7) · Germany (4) · Canada (1) · France (1) · Netherlands (1) · United Kingdom (1)
Cedrik Britten, M.D. (4) · Cedrik Britten, MD (1) · Cedrik Britten, MD, PhD (1)